Haemonetics - HAE Stock Forecast, Price & News

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Analyst Ratings Changes

Several brokerages have issued reports on HAE. JMP Securities upped their target price on Haemonetics from $80.00 to $90.00 and gave the company a "market outperform" rating in a report on Thursday, August 11th. Raymond James upped their price target on Haemonetics from $76.00 to $88.00 and gave the company an "outperform" rating in a research note on Thursday, August 11th. Morgan Stanley upped their price target on Haemonetics from $70.00 to $74.00 and gave the company an "equal weight" rating in a research note on Thursday, August 11th. Barrington Research upped their price target on Haemonetics from $77.00 to $88.00 and gave the company an "outperform" rating in a research note on Thursday, August 11th. Finally, Citigroup upped their price target on Haemonetics to $74.00 in a research note on Monday. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Haemonetics has an average rating of "Moderate Buy" and an average target price of $82.80.

Haemonetics Stock Down 0.1 %

Shares of HAE traded down $0.10 during mid-day trading on Wednesday, reaching $76.22. The company's stock had a trading volume of 5,753 shares, compared to its average volume of 410,934. Haemonetics has a 12-month low of $43.50 and a 12-month high of $77.08. The stock has a market cap of $3.91 billion, a PE ratio of 58.26 and a beta of 0.39. The company has a debt-to-equity ratio of 0.99, a current ratio of 3.81 and a quick ratio of 2.27. The company's 50 day moving average is $66.39 and its 200 day moving average is $60.24.

Haemonetics (NYSE:HAE - Get Rating) last released its quarterly earnings data on Wednesday, August 10th. The medical instruments supplier reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.51 by $0.07. Haemonetics had a return on equity of 18.62% and a net margin of 6.60%. The business had revenue of $261.50 million for the quarter, compared to the consensus estimate of $249.00 million. During the same quarter in the prior year, the business posted $0.50 EPS. The business's revenue for the quarter was up 14.4% on a year-over-year basis. Equities analysts anticipate that Haemonetics will post 2.77 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mark W. Kroll sold 8,016 shares of the firm's stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $73.71, for a total transaction of $590,859.36. Following the transaction, the director now owns 16,231 shares in the company, valued at approximately $1,196,387.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Christopher Simon sold 1,148 shares of the firm's stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $62.60, for a total transaction of $71,864.80. Following the transaction, the chief executive officer now owns 213,724 shares in the company, valued at approximately $13,379,122.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark W. Kroll sold 8,016 shares of the firm's stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $73.71, for a total value of $590,859.36. Following the transaction, the director now owns 16,231 shares in the company, valued at approximately $1,196,387.01. The disclosure for this sale can be found here. Insiders have sold 15,091 shares of company stock worth $1,016,133 in the last quarter. 1.65% of the stock is owned by insiders.